Eli Lilly Acquires Kelonia for $3.25 Billion to Strengthen Cancer and Autoimmune Treatment R&D
Eli Lilly is acquiring Kelonia Therapeutics for $3.25 billion, aiming to advance cell therapies for cancer and autoimmune diseases. The deal underscores Lilly's strategy to lead in innovative biotech and cancer treatment development.
· 46d ago
